Orally Assimilable Or Injectable Composition Patents (Class 424/643)
-
Publication number: 20120070422Abstract: A method wherein subjects having or at risk for having hyperopia, presbyopia or astigmatism are administered a composition having an effective amount of ocular antioxidants, including specifically macular pigments, to prevent, treat, or delay the onset of age-related macular degeneration (AMD).Type: ApplicationFiled: September 21, 2011Publication date: March 22, 2012Applicant: KEMIN INDUSTRIES, INC.Inventor: Richard Roberts
-
Publication number: 20120058055Abstract: A method of providing zinc to a subject in need of treatment includes administering to the subject an effective amount of a sustained-release zinc composition.Type: ApplicationFiled: November 2, 2011Publication date: March 8, 2012Inventor: Dennis Buel Crouch
-
Patent number: 8128959Abstract: The present invention provides a polymeric agent which can incorporate a large amount of a drug, accumulate selectively in a tumor site, and has a molecular size of more than that for renal excretion. A metalloporphyrin derivative (such as zinc protoporphyrin) is associated with a styrene-maleic acid copolymer via non-covalent bond to give a SMA micelle complex, allowing provision of a polymeric pharmaceutical agent for treatment of cancer with a large amount of the drug incorporated. The SMA micelle complex can be produced by a method, wherein the metalloporphyrin derivative reacts with the styrene-maleic acid copolymer in the absence of a condensation agent under an alkaline condition, solubilized, adjusted to have a pH of 6-8, and subjected to a procedure for separating a polymer component to recover the micelle complex component for the polymeric pharmaceutical agent.Type: GrantFiled: April 13, 2006Date of Patent: March 6, 2012Assignee: Hiroshi MaedaInventors: Hiroshi Maeda, Khaled Greish
-
Publication number: 20120052132Abstract: A nutritional supplement composition having therapeutically effective amounts of milk minerals including calcium, a protein source including kappa-casein fragment 106-169, and enzyme-inhibiting peptides is provided for the treatment of body weight conditions. The nutritional supplement composition is administered in amounts effective for limiting weight gain and/or enhancing weight loss, as well as promoting overall good health, in the treatment of body weight conditions, including overweight and obesity.Type: ApplicationFiled: November 7, 2011Publication date: March 1, 2012Applicant: University of Tennessee Research FoundationInventors: Michael B. Zemel, Loren S. Ward, Eric D. Bastian, Starla J. Paulsen
-
Patent number: 8119168Abstract: Disclosed are compositions comprising an effective amount of a zinc containing material having an aqueous solubility within the composition of less than about 25% by weight at 25° C.; from about 5% to about 50% of a surfactant; and from about 40% to about 95% water; wherein the pH of the composition is greater than about 7. Further disclosed are compositions comprising an effective amount of a zinc containing material having an aqueous solubility within the composition of less than about 25% by weight at 25° C.; from about 5% to about 50% of a surfactant; and from about 0.1% to about 5% of a zinc ionophoric material; from about 40% to about 95% water; and wherein the pH of the composition is greater than about 7.Type: GrantFiled: March 18, 2003Date of Patent: February 21, 2012Assignee: The Procter & Gamble CompanyInventors: Eric Scott Johnson, Elizabeth Ann Crane, James Robert Schwartz, Carl Hinz Margraf, III, Gregory V. Tormos, David Thomas Warnke
-
Publication number: 20120040012Abstract: The present invention relates to a composition and uses thereof for treatment of damaged tissue comprising at least one essential amino acid in L form and at least one essential lipid; wherein the composition is administered to a mammal suffering from severe tissue damage. The invention further relates to a composition and uses thereof comprising the mixture of one or more free L-amino acids in which the molar ratio of the free L-amino acids corresponds to the molar ratio of amino components in a mammalian tissue protein; and at least one essential lipid.Type: ApplicationFiled: October 24, 2011Publication date: February 16, 2012Applicant: IMMUNOPATH PROFILE, INC.Inventor: Leonard S. Girsh
-
Patent number: 8114441Abstract: A nutritional or pharmaceutical composition containing a fat component, a protein component and a carbohydrate component and comprising whey and casein. The composition has a weight ratio of casein to whey is 1:1 to 1:2.4 and that the composition contains: a) at least 3 grams arginine per 100 grams protein; b) at least 10 wt. % linoleic acid based on total fatty acids; c) at least 1 wt. % alpha linolenic acid based on total fatty acids; d) at least one long chain-polyunsaturated fatty acid in an amount exceeding 0.1 wt. % based on total fatty acids. The long chain polyunsaturated fatty acid being docosahexaenoic acid, arachidonic acid and eicosapentaenoic acid; e) 5 to 25 wt. % of at least one polyunsaturated fatty acid based on total fatty acids; and f) 2 to 12 grams indigestible oligosaccharides having a degree of polymerization of 2 to 100 per 100 gram dry weight of the composition. The composition reduces—among others—the risks attached to feeding whey dominant infant formula.Type: GrantFiled: August 19, 2005Date of Patent: February 14, 2012Assignee: N.V. NutriciaInventors: Günther Boehm, Christopher Beermann, Bernd Stahl, Laura M'rabet, Johan Garssen
-
Publication number: 20120034177Abstract: Disclosed are: a skin whitening agent comprising, as an active ingredient, a complex of carbonic acid and/or bicarbonic acid, a metal and an LF, a decomposition product of the complex, or a complex of carbonic acid and/or bicarbonic acid, a metal and a decomposition product of an LF; and a food, beverage, feed or cosmetic comprising the skin whitening agent. The skin whitening agent can be ingested safely on a daily basis, and exhibits an excellent skin whitening effect.Type: ApplicationFiled: October 14, 2011Publication date: February 9, 2012Applicant: SNOW BRAND MILK PRODUCTS CO., LTD.Inventors: Tatsuya WATANABE, Ken KATO, Hiroshi UENO, Yuko HARUTA, Noriko UEDA, Toshimitsu YOSHIOKA
-
Publication number: 20120027832Abstract: A molluscicidal composition, comprising: a molluscicide; a molluscicidal activity promoting additive comprising a calcium-containing salt of ethylene disuccinic acid or calcium ions and ethylenediamine disuccinic moieties, having at least 1 mole of calcium per mole of ethylenediamine disuccinic acid; and a carrier material edible to molluscs.Type: ApplicationFiled: January 26, 2010Publication date: February 2, 2012Inventors: Nicholas John Dixon, Derek Bassett, Reinhard Arndt, Andreas Prokop, Diana Parker, Tianye Chen
-
Publication number: 20120021014Abstract: Metal particulates capable of generating low levels of corrosion current beneficial for pharmaceutical, cosmetic and other medical uses are provided.Type: ApplicationFiled: July 20, 2011Publication date: January 26, 2012Inventors: Jeannette Chantalat, Jeffrey C. Geesin, James E. Hauschild, Julia Hwang, Wei Kong, Jue-Chen Liu, William R. Parrish, Michael D. Southall, Brooks Story, Ying Sun, Chunlin Yang
-
Patent number: 8092840Abstract: A nutritional supplement for enhancing sleep and lucid dreaming in humans. It contains a combination of ingredients in proportions calculated to enhance lucid dreaming. The primary ingredients are Calea ternifolia, L-5-Hydroxytryptophan (L-5-HTP), and Vinpocetine. In addition, the nutritional supplement may include the secondary ingredient Melatonin and the tertiary ingredients Wild Lettuce Extract, Mugwort Extract, Dimethylaminoethanol Powder (DMAE), Passionflower Extract and Green Tea Extract. Further, various Vitamins may be added such as certain B vitamins, D and C, as well as Zinc, Magnesium and Calcium. The selection and amounts of the ingredients of the nutritional supplement promotes sleep and lucid dreaming in people who have taken the nutritional supplement prior to going to sleep.Type: GrantFiled: October 30, 2007Date of Patent: January 10, 2012Inventor: Jeff Luciano
-
Patent number: 8093210Abstract: A pharmaceutical composition comprising 5-ethyl-1-phenyl-2-(1H)-pyridone (5-EPP) and its use for the treatment of sepsis are disclosed.Type: GrantFiled: March 9, 2009Date of Patent: January 10, 2012Assignee: Solanan, Inc.Inventors: Solomon B. Margolin, Shri N. Giri, legal representative, Shri N. Giri
-
Publication number: 20110300192Abstract: Magnesium oxide granules which are excellent in dissolution property, are palatable, rarely leave any rough feeling in the oral cavity and have a good color in appearance. The granules comprise magnesium oxide particles which are represented by the following formula (1) and have an average secondary particle diameter of 0.1 to 25 ?m and an apparent specific volume of 3 to 20 ml/g, a sugar alcohol and a disintegrating agent. (Mg2+1-xZn2+x)O??(1) (In the formula, X is a numeral of 0 to 0.02.Type: ApplicationFiled: February 19, 2010Publication date: December 8, 2011Inventors: Hideaki Kitajima, Naruhito Kawanabe
-
Patent number: 8034799Abstract: Methods are provided for reducing copper values for, by way of example, treating, preventing or ameliorating tissue damage such as, for example, tissue damage that may be caused by (i) disorders of the heart muscle (for example, cardiomyopathy or myocarditis) such as idiopathic cardiomyopathy, metabolic cardiomyopathy which includes diabetic cardiomyopathy, alcoholic cardiomyopathy, drug-induced cardiomyopathy, ischemic cardiomyopathy, and hypertensive cardiomyopathy, (ii) atheromatous disorders of the major blood vessels (macrovascular disease) such as the aorta, the coronary arteries, the carotid arteries, the cerebrovascular arteries, the renal arteries, the iliac arteries, the femoral arteries, and the popliteal arteries, (iii) toxic, drug-induced, and metabolic (including hypertensive and/or diabetic disorders of small blood vessels (microvascular disease) such as the retinal arterioles, the glomerular arterioles, the vasa nervorum, cardiac arterioles, and associated capillary beds of the eye, the kidneyType: GrantFiled: September 7, 2005Date of Patent: October 11, 2011Assignee: Philera New Zealand LimitedInventors: Garth J. S. Cooper, John R. Baker
-
Publication number: 20110229585Abstract: The invention provides a nutrient composition for augmenting immune strength or physiological detoxification. The nutrient composition consists of an optimal combination of an effective amount of at least one vitamin antioxidant, at least one mineral antioxidant and a highly saturable amount of at least three high potency antioxidants. The at least one vitamin antioxidant can be vitamin C, bioflavonoid complex, vitamin E, vitamin B6 or beta-carotene and the at least one mineral antioxidant can be zinc or selenium. The at least three high potency antioxidants can be alpha lipoic acid, acetyl L-carnitine, N-acetyl-cysteine, co-enzyme Q10 or glutathione. Also provided is a nutrient composition for augmenting immune strength or physiological detoxification that consists of an optimal combination of an effective amount of at least three vitamin antioxidants, at least two mineral antioxidants and a highly saturable amount of at least three high potency antioxidants.Type: ApplicationFiled: May 27, 2011Publication date: September 22, 2011Inventor: Jon D. Kaiser
-
Publication number: 20110212189Abstract: A sustained-release zinc composition preferably includes potassium bicarbonate. A method of providing zinc to a subject in need of treatment includes administering to the subject an effective amount of a sustained-release zinc composition which preferably includes potassium bicarbonate.Type: ApplicationFiled: November 1, 2010Publication date: September 1, 2011Applicant: ADEONA PHARMACEUTICALS, INC.Inventors: George J. BREWER, Steve H. KANZER, David A. NEWSOME
-
Patent number: 8007832Abstract: A composition and method for treating mammals suffering from malignant tumors which involves administering a composition including ammoniated mercury, zinc oxide and citric acid.Type: GrantFiled: August 16, 2006Date of Patent: August 30, 2011Inventors: Yousef Haik Babikian, Walid Adib Taybeh
-
Patent number: 7994217Abstract: Multivitamin/Multimineral supplements are provided for supplementing iron and desirable nutrients in the diet of mammals. The supplements include an iron-amino acid chelate, a form of iron more bioavailable than traditional iron salts. The supplements may further include a pharmaceutically accepted salt form of iron as well as other nutritional vitamins and minerals. The supplements are useful for providing iron for pregnant and lactating females as well as for persons suffering from anemia.Type: GrantFiled: February 27, 2003Date of Patent: August 9, 2011Assignee: Xanodyne Pharmaceuticals, Inc.Inventors: Prasad Nidamarty, William R. Hurd, Roland J. Bydlon, William C. Williams, Michael Dempsey, Amy Erbskorn
-
Publication number: 20110177010Abstract: Two-phase preparation for temporally gradual administration comprising a) a phase (A) comprising water soluble vitamins and/or the corresponding provitamins, wherein phase (A) does not contain liposoluble vitamins or provitamins corresponding to liposoluble vitamins, b) a phase (B) comprising vitamins and/or the corresponding provitamins, wherein the quantity of liposoluble vitamin compounds is larger than the quantity of water soluble vitamin compounds.Type: ApplicationFiled: January 4, 2011Publication date: July 21, 2011Inventor: Tanja Lautenschläger
-
Publication number: 20110151022Abstract: The current invention provides novel thiotungstate derivatives, methods of making novel thiotungstate derivatives, pharmaceutical compositions of novel thiotungstate derivatives, methods of using novel thiotungstate derivatives to treat diseases associated with aberrant vascularization, copper metabolism disorders and obesity and methods of using pharmaceutical compositions of thiotungstate derivatives to treat diseases associated with aberrant vascularization, copper metabolism disorders, neurodegenerative disorders, obesity or NF-?B dysregulation.Type: ApplicationFiled: December 13, 2010Publication date: June 23, 2011Inventors: Robert J. Ternansky, Patricia L. Gladstone, Amy L. Allan, Melissa L.P. Price, Andrew P. Mazar
-
Publication number: 20110129548Abstract: The present invention provides compositions comprising beta-1,3/1,6-D-glucan and an additive (e.g., Vitamin D, Zinc, etc.) and methods of use, e.g., enhancing the immunocompetence of animals, e.g., humans, comprising administering the compositions of the invention to the animals.Type: ApplicationFiled: October 19, 2007Publication date: June 2, 2011Applicant: BioAgra, LLCInventors: Nino Sorgente, Daniel Moothart
-
Publication number: 20110117191Abstract: The invention relates to a substance mixture on the basis of a mixture of essential oils, wherein the oil mixture contains juniper oil and turpentine oil, in particular turpentine oil of the duster pine type or substantially comprises them, and wherein the substance mixture preferably furthermore contains a liquid and/or dissolved active ingredient or a mixture of a plurality thereof and/or an active ingredient in powder form or a mixture of a plurality thereof.Type: ApplicationFiled: October 13, 2010Publication date: May 19, 2011Inventor: Marianne Brøndlund
-
Publication number: 20110117210Abstract: The present invention is a non-topical method of therapeutically treating human cancer patients which comprises an administration of an anti-cancer medicament comprising at least one simple organic or inorganic salt of zinc in at least a minimally effective concentration to suppress malignant tumor growth and induce tumor regression in-vivo. Administration can be performed by oral, parenteral, and/or body cavity routings; and the therapeutic treatment method is effective for the treatment of a diverse range of primary human cancers and metastatic diseases.Type: ApplicationFiled: November 17, 2009Publication date: May 19, 2011Inventor: Andrey Ugolkov
-
Publication number: 20110052694Abstract: Described herein are microneedle drug delivery systems comprising a pharmaceutical compositions comprising pharmaceutically active agents (e.g., cannabidiol and prodrugs of cannabidiol) and microneedle arrays suitable for local and systemic delivery of the active agent to a mammal. Also described herein are methods of using a microneedle transdermal or topical drug delivery systems comprising pharmaceutical compositions, comprising cannabidiol and prodrugs of cannabidiol, and microneedle arrays in the treatment disease, including pancreatitis and pancreatic cancer.Type: ApplicationFiled: August 31, 2010Publication date: March 3, 2011Applicant: ALLTRANZ INC.Inventors: Audra Lynn Stinchcomb, Stan Lee Banks, Miroslaw Jerzy Golinski, Jeffery Lynn Howard, Dana Carmel Hammell
-
Publication number: 20110040144Abstract: Methods and apparatus are described for diet and weight loss control by altering the senses of smell and taste. Olfactory nerves are ablated in a localized area at the top of the nasal cavity, resulting in a loss of smell, which also decreases the sense of taste and results in a reduced appetite, enabling a patient to eat less and lose weight. After several months the nerves begin to regenerate, and the sense of smell and taste return, although a repeat ablation can be performed if necessary, such as if new dietary habits have not yet been firmly established.Type: ApplicationFiled: August 14, 2010Publication date: February 17, 2011Inventor: Milton S. Jackson
-
Publication number: 20110008291Abstract: The present invention provides a novel method for treating oral conditions and upper gastrointestinal conditions in a subject by providing an inventive oral dosage form of a pharmaceutical composition comprising an effective amount of at least one antifungal and optionally a flavor modifier and/or salivation component such as an herbal component. In the present invention, the subjects have either not been diagnosed or do not have active or recurrent fungal infections. Specifically, the present invention is directed to chewable dosage forms.Type: ApplicationFiled: August 16, 2010Publication date: January 13, 2011Inventor: Stuart L. Weg
-
Patent number: 7867523Abstract: A pharmaceutical composition for the treatment of colds and influenza. The pharmaceutical composition is a mixture of: acetaminophen, diphenhydramine, dextromethorphan, arabinogalactan, vitamin C, zinc, olive leaf extract, resveratrol and elderberry extract.Type: GrantFiled: July 18, 2008Date of Patent: January 11, 2011Inventor: Elaine A. Vanterpool
-
Publication number: 20100330197Abstract: The present invention provides an oral or enteral composition incorporating not only BCAA but other nutrients to be conducive to comprehensive recovery from fatigue, and improvement in total physical condition. The oral or enteral composition is formulated as a composite of a branched-chain amino acid, coenzyme Q10, L-carnitine, a citric acid, and zinc.Type: ApplicationFiled: February 19, 2009Publication date: December 30, 2010Applicants: EARNEST MEDICINE CO., LTD., OTSUKA PHARMACEUTICAL FACTORY, INC.Inventors: Takashi Higashiguchi, Takako Hatakeyama
-
Patent number: 7858602Abstract: A method for the treatment and prophylaxis of conditions of aging due oxidative stress and as growth factors of stem cells. Such conditions due to oxidative stress are associated with a decreased presence of one or more cell-specific carbonic anhydrase enzymes in the tissue of a subject. Such conditions include but are not limited to alzheimer's disease, parkinson's disease, multiple sclerosis, autism, lou gehrig's disease, huntington's disease, diabetes mellitus, amyloid diseases, atherosclerosis, arthritis, osteoporosis, cystic fibrosis. The method comprises administering to the patient a pharmaceutically effective, non-toxic amount of one or more compounds that increases the presence of one or more Carbonic Anhydrase Isozymes whose levels have been reduced in the subject.Type: GrantFiled: May 12, 2007Date of Patent: December 28, 2010Inventor: Victorio C. Rodriguez
-
Publication number: 20100323032Abstract: An agent for treating ulcer containing, as an effective component, a particulate composite hydrotalcite obtained by solidly dissolving a small amount of zinc in the particulate hydrotalcite, exhibiting excellent effect for treating the peptic ulcer and, further, working as a Zn-supplying agent. The agent for treating the ulcer is represented by the following formula (1), (MgaZnb)1-xAlx(OH)2(An?)x/n.mH2O??(1) wherein An? is CO32?, SO42? or Cl?, n is 1 or 2, and x, a, b and m are values that satisfy the following conditions, 0.18?x?0.4, 0.1?a<1, 0<b?0.5, 0?m<1.Type: ApplicationFiled: December 4, 2008Publication date: December 23, 2010Inventors: Keiko Katsuki, Akira Okada
-
Patent number: 7846914Abstract: A composition and method for pain relief and the treatment and prevention of endothelial dysfunction the cause of atherosclerosis, cardiovascular disease, hypertension, and stroke in mammals comprising a therapeutically effective amount of anti-inflammatory agents comprising; NSAIDs, an amino sugar and a zinc compound combined with dietary supplements that may enhance longevity.Type: GrantFiled: February 15, 2005Date of Patent: December 7, 2010Assignee: Advanced Medical InstrumentsInventor: Edward J. Petrus
-
Patent number: 7838042Abstract: Hypoallergenic metal amino acid chelate compositions, hypoallergenic formulations containing hypoallergenic metal amino acid chelates, methods of preparing hypoallergenic metal amino acid chelate, and methods of administering hypoallergenic metal amino acid chelates are provided. Specifically, the present invention provides metal amino acid chelates that are substantially free of allergens such that administration of the metal amino acid chelates to a subject in an effective amount to cause a medicinal or nutritional result does not produce a discernable adverse allergic reaction. The metal amino acid chelates can include chelates having a naturally occurring amino acid to metal molar ratio of from about 1:1 to 4:1.Type: GrantFiled: April 21, 2004Date of Patent: November 23, 2010Assignee: Albion International, Inc.Inventors: Max R. Motyka, Rick Harnish, Stephen D. Ashmead, H. DeWayne Ashmead
-
Publication number: 20100291235Abstract: Biological medical means for treating sterile inflammatory diseases are disclosed. The invention relates to the use of L-arginine-hydrochloride (Arg) or lysine (Lys) and L-leucine (Leu) for the manufacture of a pharmaceutical composition for treating or preventing sterile inflammation. The composition further comprises trace elements chromium (Cr), tin (Sn), selenium (Se), strontium (Sr), vanadium (V), wolfram (W) and folic acid. The pharmaceutical composition can further comprise zinc (Zn) and or manganese (Mn) as well as central nervous system (CNS) lipids. Sterile inflammations are related to disorder such as fibromyalgia, Crohn's disease, psoriasis and rheuma.Type: ApplicationFiled: December 17, 2008Publication date: November 18, 2010Inventor: Thomas Tallberg
-
Publication number: 20100278940Abstract: A composition comprising at least 15%, by weight, of calcium derived from a rhodolith coralline algae; magnesium; strontium; vanadium; vitamin K; and vitamin D3.Type: ApplicationFiled: April 27, 2010Publication date: November 4, 2010Applicants: HL DISTRIBUTION COMPANYInventors: Dean Neuls, Marcos Antonio Dias Neves
-
Publication number: 20100278939Abstract: A profertility composition for administration to infertile men with sperm oxidative stress is disclosed. The composition comprises a unique combination of a pharmaceutically acceptable vitamin E, vitamin C, selenium, zinc, folic acid, lycopene and at least one carnitine source.Type: ApplicationFiled: April 30, 2010Publication date: November 4, 2010Inventor: Parviz Gharagozloo
-
Publication number: 20100255118Abstract: A preparation preferably containing zinc and sustained release copper. Additional nutrients can be included in the preparation.Type: ApplicationFiled: March 12, 2008Publication date: October 7, 2010Inventor: Steve H. Kanzer
-
Publication number: 20100227001Abstract: A method of delivering nutrients for bariatric patients comprising the sublingual administration of a B-complex vitamin composition and ingesting a liquid, water-soluble multi-vitamin complex orally at approximately the same time. The liquid multi-vitamin is comprised of a plurality of compounds from the group of Vitamin A, Vitamin C, Vitamin D and Vitamin E. After administering the Vitamin B complex and the liquid multi-vitamin, a solid vitamin formulation comprising at least two compounds from the group of iron, zinc, selenium, copper, chromium, Vitamin K, and manganese is ingested orally. A protein solution comprising proteins broken down into small peptide chains, calcium, and fiber may also be delivered orally to the bariatric patient in a liquid form. The method may be repeated once or twice daily. The method of the invention maximizes delivery and absorption of nutrients to the bariatric patient and the tolerance and speed of delivery.Type: ApplicationFiled: March 5, 2009Publication date: September 9, 2010Inventor: SILVIA DEMETER
-
Patent number: 7790203Abstract: A composition and treatment regimen for the amelioration of epidermal herpetic lesions caused by Herpes Simplex Virus (HSV-1) symptoms, Herpes Zoster, and Herpes Genitalia. The treatment includes a regimen of oral administration of a composition including from about 15 to 50 mg of zinc sulfate, from about 5 to 20 mg of magnesium sulfate, from about 15 to 60 mg of thiamin, from about 10 to 30 mg of riboflavin, from about 4 mg to 12 mg of pyridoxine hydrochloride, from about 300 to 1000 mg of ascorbic acid, from about 90 to 300 mg of niacin, and from about 20 to 70 mg of pantothenic acid. The composition and regimen may optionally include an efficacious amount of an amino acid, and preferably about 500 mg of lysine.Type: GrantFiled: December 13, 2005Date of Patent: September 7, 2010Inventor: Tom R. Lowder
-
Publication number: 20100215769Abstract: Selectively administering to humans, as a daily dosage, a combination of resveratrol-carotenoids, nicotinamide (or niacin or a precursor thereof) and a source of zinc, in excess of normal dietary levels, for improving resistance to DNA damage, enhancing DNA repair capacity, and stimulating immune function.Type: ApplicationFiled: February 24, 2009Publication date: August 26, 2010Inventors: Ronald W. Pero, Stuart Garret
-
Publication number: 20100203126Abstract: The present invention relates to a multi-layered vitamin/mineral complex tablet having enhanced stability of ubidecarenone. The present invention is characterized in that ubidecarenone is contained in a first layer, and ingredients decreasing the stability of ubidecarenone are contained in an additional layer separated from the first layer. The method is a convenient process, and the formulation prepared by the method can maintain a high content of ubidecarenone during long-term storage, thereby providing a simultaneous intake of ubidecarenone and nutritional ingredients such as various vitamins.Type: ApplicationFiled: July 11, 2008Publication date: August 12, 2010Inventors: Jong-Woo Park, Jin-Woo Han, Yae-Young Choi
-
Publication number: 20100203152Abstract: There is provided use of a mixed metal compound in the manufacture of medicament for neutralising or buffering stomach acid, wherein the mixed metal compound contains at least one trivalent metal selected from iron (III) and aluminium and at least one divalent metal selected from of magnesium, iron, zinc, calcium, lanthanum and cerium, wherein (A) the mixed metal compound is of formula (I): MII1-aMIIIaObAn-c.zH2O (I) where MII is the at least one bivalent metal; MIII is the at least one trivalent metal; An- at least one n-valent anion; 2+a=2b+?cn and ?cn<0.9a, and z is 2 or less, and/or (B) the mixed metal compound is provided in the form of a granular material comprising (i) at least 50% by weight, based on the weight of the granular material, of the mixed metal compound (ii) from 3 to 12% by weight, based on the weight of the granular material, of non-chemically bound water, and (iii) no greater than 47% by weight based on the weight of the granular material of excipient.Type: ApplicationFiled: July 24, 2008Publication date: August 12, 2010Applicant: Ineos Healthcare KimitedInventors: Maurice Sydney Newton, James David Morrison, Ruth Diane Pennell, Nigel Peter Phodes, Alexis John Toft
-
Publication number: 20100196508Abstract: The present invention relates to compositions and methods for treating the nutritional deficiencies observed in patients suffering from renal disease and associated disorders. Specifically, the method involves administering to a renal patient a composition comprising vitamin C, vitamin E, B-complex vitamins, selenium, and zinc.Type: ApplicationFiled: April 12, 2010Publication date: August 5, 2010Inventors: John A. Giordano, Charles J. Balzer
-
Patent number: 7754763Abstract: An oral spray composition for preventing and/or reducing the symptoms of the common cold including a zinc formulation containing both zinc acetate and zinc gluconate to ensure sustained availability of increased amounts of ionizable zinc.Type: GrantFiled: April 30, 2004Date of Patent: July 13, 2010Assignee: Zicam, LLCInventor: Tim Clarot
-
Publication number: 20100143498Abstract: There is provided an infusion solution for peripheral intravenous administration comprising a multichamber vessel constructed in a connectable manner, which separately houses a sugar solution containing sugars, electrolytes and vitamin B1, and an amino acid solution containing amino acids, electrolytes and a sulfite, whereby the vitamin B1 and amino acids are stably maintained. In the infusion solution for peripheral intravenous administration, the sugar solution contains calcium gluconate, contains no greater than 1.4 g/L sodium lactate, has a pH of 4.0-4.7 and has a titratable acidity of 2-4, the amino acid solution contains 4.0-8.0 g/L sodium lactate, contains no calcium gluconate, has a pH of 6.8-7.2, contains free L-cysteine as cysteine and contains 0.05-0.2 g/L sodium hydrogen sulfite, and after the sugar solution and amino acid solution have been mixed, the infusion solution has a pH of 6.5-7.1 and a titratable acidity of 5-10.Type: ApplicationFiled: November 23, 2009Publication date: June 10, 2010Applicant: Ajinomoto Co., Inc.Inventors: Mutsuo SHIGETA, Kazuhiro ABIKO
-
Publication number: 20100135950Abstract: A pharmaceutical composition comprises a pharmaceutically acceptable ferrous iron compound; an amine polymer or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier. Alternatively, a pharmaceutical composition comprises a pharmaceutically acceptable ferrous iron compound and pharmaceutically acceptable carrier, wherein the ferrous iron compound is selected from the group consisting of iron(II) acetate, iron(II) citrate, iron(II) ascorbate, iron(II) oxalate, iron(II) oxide, iron(II) carbonate, iron(II) carbonate saccharated, iron(II) formate, iron(II) sulfate, iron(II) chloride, iron(II) acetylacetonate and combinations thereof. A method of treating a subject with hyperphosphatemia comprises administering to the subject an effective amount of a pharmaceutical composition as described above.Type: ApplicationFiled: June 25, 2007Publication date: June 3, 2010Applicant: Genzyme CorporationInventors: Chad Huval, Pradeep Dhal, Stephen Randall Holmes-Farley
-
Publication number: 20100136134Abstract: A nutritional or pharmaceutical composition containing a fat component, a protein component and a carbohydrate component and comprising whey and casein. The composition has a weight ratio of casein to whey is 1:1 to 1:2.4 and that the composition contains: a) at least 3 grams arginine per 100 grams protein; b) at least 10 wt. % linoleic acid based on total fatty acids; c) at least 1 wt. % alpha linolenic acid based on total fatty acids; d) at least one long chain-polyunsaturated fatty acid in an amount exceeding 0.1 wt. % based on total fatty acids. The long chain polyunsaturated fatty acid being docosahexaenoic acid, arachidonic acid and eicosapentaenoic acid; e) 5 to 25 wt. % of at least one polyunsaturated fatty acid based on total fatty acids; and f) 2 to 12 grams indigestible oligosaccharides having a degree of polymerisation of 2 to 100 per 100 gram dry weight of the composition. The composition reduces—among others—the risks attached to feeding whey dominant infant formula.Type: ApplicationFiled: August 19, 2005Publication date: June 3, 2010Applicant: N.V. NutriciaInventors: Günther Boehm, Christopher Beermann, Bernd Stahl, Laura M'rabet, Johan Garssen
-
Publication number: 20100015118Abstract: A body supplement and method for improving blood flow, muscle chemistry and/or the oxygenation of muscles, said supplement including cinchona bark or quinine in the range of approximately 0.0010 grams and 4.0 grams per dosage.Type: ApplicationFiled: July 15, 2009Publication date: January 21, 2010Inventors: Anthony J. Hadala, Lewis E. Bennett, D.C.
-
Publication number: 20100015248Abstract: A pharmaceutical composition for the treatment of colds and influenza. The pharmaceutical composition is a mixture of: acetaminophen, diphenhydramine, dextromethorphan, arabinogalactan, vitamin C, zinc, olive leaf extract, resveratrol and elderberry extract.Type: ApplicationFiled: July 18, 2008Publication date: January 21, 2010Inventor: Elaine A. Vanterpool
-
Publication number: 20100009012Abstract: A chewable composition for treating pharyngeal inflammation is provided that includes a first chewable prostaglandin inhibitor tablet that includes a prostaglandin inhibitor along with those excipients needed to form a compressed chewable tablet. The first chewable tablet is devoid of ascorbic acid, citric acid, and zinc cations. A second chewable supplement tablet of the composition includes an immune system activating organic acid of ascorbic acid, citric acid, or a combination thereof. The second chewable supplement tablet also includes zinc cations. The components of the second chewable supplement tablet are readily segregated into multiple tablets, with each of the multiple tablets containing similar or dissimilar active ingredient constituents and concentrations.Type: ApplicationFiled: July 13, 2009Publication date: January 14, 2010Inventor: N. David Zukkoor
-
Publication number: 20090297627Abstract: A process to improve performance of an individual during a long term sporting event includes the steps of providing in ingestible form a plurality of doses of a first nutritional composition, each dose including a known equivalent concentration of calcium, magnesium, potassium, and zinc; providing in ingestible form a plurality of doses of a second nutritional composition, each dose of the second nutritional composition including a known equivalent concentration of calcium, magnesium, potassium, sodium, and zinc; establishing a dietary meal plan including the first nutritional composition for the individual to establish a urine pH in the range of 6.5 to 7.5; following the dietary meal plan to establish a urine pH in the range of 6.5 to 7.5; and, periodically measuring urine pH to confirm a urine pH in the range of 6.5 to 7.5.Type: ApplicationFiled: May 27, 2008Publication date: December 3, 2009Inventor: Darrell L. Tanelian